Amgen severs 14-year Cytokinetics partnership, bailing on omecamtiv after mixed PhIII results
Amgen is shrugging off a 14-year development alliance and the tens of millions of dollars spent to develop a new heart drug at Cytokinetics after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
